Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | USP5 | P45974 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719072 | 0.86 | POLB (0.67) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL28359260 | 0.85 | KDM4E (0.63) | ALDH1A1KDM4ESMN1; SMN2HTTRECQL | |
| SCHEMBL24221018 | 0.84 | HTT (0.73) | ALDH1A1KDM4ESMN1; SMN2HTTRECQL | |
| SCHEMBL165947 | 0.82 | ALDH1A1 (0.67) | ALDH1A1KDM4ESMN1; SMN2USP5HPGD | |
| SCHEMBL16912986 | 0.82 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2HTTRECQLLMNA | |
| SCHEMBL521556 | 0.81 | KMT2A (0.64) | ALDH1A1KDM4EMEN1KMT2AGAA | |
| SCHEMBL8187563 | 0.81 | SMN1; SMN2 (0.54) | ALDH1A1KDM4ESMN1; SMN2HTTRECQL | |
| SCHEMBL17007440 | 0.80 | KDM4E (0.56) | ALDH1A1KDM4ESMN1; SMN2USP5HTT | |
| SCHEMBL1474049 | 0.78 | LMNA (0.78) | ALDH1A1KDM4ESMN1; SMN2HTTRECQL | |
| SCHEMBL25107871 | 0.78 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-09-05 | — | — | US | disclosed |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180291000-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2018-10-11 | — | — | US | disclosed |
| CN-103270023-B | 4- { [ (pyridin-3-yl-methyl) aminocarbonyl ] amino } benzene-sulfone derivatives as NAMPT inhibitors for the treatment of diseases such as cancer | 福马TM有限责任公司 | 2016-11-02 | — | — | CN | disclosed |
| EP-2611777-B1 | N-(4-{[PYRIDIN-3-YL-METHYL)CARBAMOYL]AMINO}BENZENE-SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM LLC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | ALDH1A1 511/4885KDM4E 813/4885SMN1; SMN2 550/4885 |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | ALDH1A1 660/4885KDM4E 1450/4885SMN1; SMN2 1174/4885 |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | ALDH1A1 511/4885KDM4E 813/4885SMN1; SMN2 550/4885 |
| US-20180291000-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | ALDH1A1 660/4885KDM4E 1450/4885SMN1; SMN2 1174/4885 |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | ALDH1A1 511/4885KDM4E 813/4885SMN1; SMN2 550/4885 |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | ALDH1A1 660/4885KDM4E 1450/4885SMN1; SMN2 1174/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | ALDH1A1 1273/4885KDM4E 2133/4885SMN1; SMN2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.